ROVI updates its strategy in a meeting with shareholders, investors and analysts
Wed, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Related
ROVI REACHED 201.9 MILLION EUROS OF REVENUE IN THE FIRST POST-PANDEMIC QUARTER
Operating revenue decreased by 2% to 201.6 million...
3 min
10/05/2023
ROVI COMMENCES CLINICAL DEVELOPMENT OF A NEW THREE-MONTHLY FORMULATION OF LETROZOLE (LETROZOLE LEBE)
The objective of the new...
6 min
25/04/2023
Madrid, 12 April, 2023
The Universidad Pontificia Comillas, in collaboration with Laboratorios Farmacéuticos ROVI, has created...
3 min
12/04/2023
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.